Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Furthering cell therapy ambition across oncology and autoimmune diseases
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
The peptide-based vaccine induces a t cell-dependent response
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Subscribe To Our Newsletter & Stay Updated
